Analyst Ratings For Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)
Today, HC Wainwright set its price target on Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) to $11.00 per share.
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) is Buy with a consensus target price of $10.00 per share, a potential 143.31% upside.
Some recent analyst ratings include
Recent Insider Trading Activity For Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has insider ownership of 24.70% and institutional ownership of 8.29%.
- On 3/15/2018 June Sherie Almenoff, Director, bought 5,700 with an average share price of $3.50 per share and the total transaction amounting to $19,950.00.
- On 3/15/2018 Ralph Dr. Kern, COO, bought 5,000 with an average share price of $3.60 per share and the total transaction amounting to $18,000.00.
- On 8/31/2017 Irit Arbel, Director, bought 2,500 with an average share price of $4.26 per share and the total transaction amounting to $10,650.00.
- On 8/23/2017 Uri Yablonka, EVP, bought 2,000 with an average share price of $3.98 per share and the total transaction amounting to $7,960.00.
- On 12/16/2015 Robert G L Shorr, Director, sold 10,800 with an average share price of $2.71 per share and the total transaction amounting to $29,268.00.
- On 12/15/2015 Malcolm S. Taub, Director, sold 41,742 with an average share price of $2.60 per share and the total transaction amounting to $108,529.20.
- On 12/11/2015 Malcolm S. Taub, Director, sold 13,480 with an average share price of $2.73 per share and the total transaction amounting to $36,800.40.
About Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Recent Trading Activity for Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)
Shares of Brainstorm Cell Therapeutics Inc closed the previous trading session at 4,12 +0,030 0,73 % with 4.13 shares trading hands.